Measles and BCG Vaccines for Mother and Child

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age15-35
SponsorBandim Health Project

About this trial

In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other infections: they have beneficial "non-specific effects". The investigators have now seen signs that these non-specific effects for children are stronger if their mother has been given the same vaccines.

In Africa, BCG vaccine is recommended at birth and measles vaccine at 9 months of age. They are not used beyond childhood.

The investigators will randomize 2400 women to BCG vaccine, measles vaccine, or placebo. The investigators will further randomize their children to an extra early measles vaccine or placebo. The investigators will assess which of the resulting six vaccination schedules are best for women's and children's protection against measles, for the child's immune system, and for general health.

The project will be the first in the world to investigate the importance of vaccinating women with live vaccines.

Eligibility criteria

Qualifiers

Female women in the fertile age

Non-pregnant

HIV-negative

Living in the BHP HDSS study area

Disqualifiers

Positive pregnancy test

Positive HIV test

Tuberculosis (previous or current)

Immunodeficiency

Trial design

Treatments tested in this trial

  • BCG vaccine
  • Measles vaccine
  • Placebo

Treatment groups

2,400 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Bandim Health Project

Lead sponsor

The University of Western Australia

Collaborator

Université Libre de Bruxelles

Collaborator